(BAY 1000394/14484) An Open-Label, Phase I, Dose-Escalation Study to Characterize the Safety,Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given in a 3 Days on / 4 Days off Schedule in Subjects with Advanced Malignancies
Description: 

To define the safety profile, MTD , pks and biomarkerand tumor response profile in subjects with advanced malignancies.

Study Number: 

PH 217312

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01188252

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.